ABOUT BRONCHIAL THERMOPLASTYPATIENT STORIESTAKE ACTION
©2018 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners.Right to Breathe is a patient advocacy initiative sponsored by Boston Scientific Corporation.
1 Wenzel, Sally. Severe Asthma in Adults. American Journal of Respiratory and Critical Care Medicine. VOL 172 2005. And www.cdc.gov/asthma/most_recent_data.htm 2 Chipps et al. Journal of Allergy and Clinical Immunology August 2017 More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II. Bradley E. Chipps, MD,a Tmirah Haselkorn, PhD,b Brandee Paknis, PharmD,c Benjamin Ortiz, MD,c Eugene R. Bleecker, MD,d Farid Kianifard, PhD,c Aimee J. Foreman, MA,e Stanley J. Szefler, MD,f and Robert S. Zeiger, MD, PhD,g for the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens Study Group Sacramento, Los Altos, San Francisco, and San Diego, Calif; East Hanover, NJ; Winston-Salem, NC; and Aurora, Colo 3 Castro M, et al, for the AIR2 Trial Study Group. Am J Respir Crit Care Med. 2010;181:116-124.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
Brief Statement of Relevant Indications for Use, Contraindications, Warnings, and Adverse Events: The Alair Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists. The Alair System is not for use in patients with an active implantable electronic device or known sensitivity to medications used in bronchoscopy. Previously treated airways of the lung should not be retreated with the Alair System. Patients should be stable and suitable to undergo bronchoscopy. The most common adverse event of BT is an expected transient increase in the frequency and worsening of respiratory-related symptoms. ENDO-551804-AA May 2018
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician. Refer to Prescriptive Information for Indications for Use, Contraindications, Potential Complications and Warnings and Precautions.
ENDO-552203-AA June 2018